Phillyrin improves myocardial remodeling in salt-sensitive hypertensive mice by reducing endothelin1 signaling

被引:1
作者
Luo, Qingman [1 ]
Liu, Qiao [2 ]
Tang, Kecheng [1 ]
Zhong, Bin [1 ]
Yang, Shengqian [1 ,3 ,4 ]
Li, Xiaohui [1 ,3 ,4 ]
机构
[1] Army Med Univ, Inst Mat Med, Coll Pharm, Dept Pharmaceut, Gao Tan Yan St 30, Chongqing 400038, Peoples R China
[2] Chongqing Med & Pharmaceut Coll, Dept Pharmaceut, Chongqing 401331, Peoples R China
[3] Army Med Univ, Coll Pharm, Chongqing Engn Res Ctr Pharmacodynam Evaluat, Dept Pharmaceut, Chongqing 400038, Peoples R China
[4] Army Med Univ, Inst Mat Med, Coll Pharm, Chongqing Engn Res Ctr Pharmacodnam Evaluat, Gao Tan Yan St 30, Chongqing 400038, Peoples R China
关键词
phillyrin; myocardial remodeling; salt-sensitive hypertension; endothelin1; HEART; INFLAMMATION; RATS;
D O I
10.1093/jpp/rgae018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives Prolonged exposure to chronic hypertension places the heart under excessive strain, resulting in myocardial remodeling. Phillyrin, derived from the natural plant Forsythia suspensa, has been found to possess cardioprotective properties. The objective of this study is to investigate the role and mechanism of phillyrin in hypertension-induced myocardial remodeling in mice.Methods We constructed a mouse model of salt-sensitive hypertension. The mice were treated with varying doses of phillyrin, and their blood pressure, cardiac function, cardiac hypertrophy, fibrosis, inflammation, and other conditions were assessed.Key findings Our research findings demonstrated that phillyrin has the potential to lower blood pressure, enhance cardiac function, and mitigate cardiac hypertrophy, fibrosis, and inflammatory responses in deoxycorticosterone acetate-salt hypertension mice. In hypertensive mice, there was an elevated expression of endothelin1 (ET-1) in heart tissue, which can be reduced by phillyrin. Additionally, phillyrin effectively reduced the hypertrophy of H9c2 cells induced by ET-1 stimulation.Conclusions Our research highlights the therapeutic capabilities of phillyrin in the treatment of myocardial remodeling through the reduction of ET-1 signaling. These results contribute to the advancement of novel applications for phillyrin and establish a solid conceptual basis for future investigations in this area.
引用
收藏
页码:672 / 680
页数:9
相关论文
共 27 条
  • [1] Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats:: Role of ETA receptors
    Ammarguellat, FZ
    Gannon, PO
    Amiri, F
    Schiffrin, EL
    [J]. HYPERTENSION, 2002, 39 (02) : 679 - 684
  • [2] Arterial Stiffness and Cardiovascular Risk in Hypertension
    Boutouyrie, Pierre
    Chowienczyk, Phil
    Humphrey, Jay D.
    Mitchell, Gary F.
    [J]. CIRCULATION RESEARCH, 2021, 128 (07) : 864 - 886
  • [3] Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats
    Chan, Vincent
    Hoey, Andrew
    Brown, Lindsay
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (07) : 902 - 908
  • [4] Endothelin 1 Activation of Endothelin A Receptor/NADPH Oxidase Pathway and Diminished Antioxidants Critically Contribute to Endothelial Progenitor Cell Reduction and Dysfunction in Salt-Sensitive Hypertension
    Chen, Dan-Dan
    Dong, Yu-Gang
    Yuan, Hong
    Chen, Alex F.
    [J]. HYPERTENSION, 2012, 59 (05) : 1037 - +
  • [5] Cutland CL., 2023, J HEART LUNG TRANSPL
  • [6] A Simplified Herbal Formula Improves Cardiac Function and Reduces Inflammation in Mice Through the TLR-Mediated NF-κB Signaling Pathway
    Dong, Xiaoming
    Han, Xiaowei
    Zhang, Xiaojiao
    Li, Sijing
    Li, Ziru
    Kang, Jinhua
    Jiang, Jialin
    Ni, Shihao
    Lu, Lu
    He, Zhiling
    Huang, Haoming
    Xian, Shaoxiang
    Yuan, Tianhui
    Yang, Zhongqi
    Long, Wenjie
    Wan, Zemin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Developmental endothelial locus-1 protects from hypertension-induced cardiovascular remodeling via immunomodulation
    Failer, Theresa
    Amponsah-Offeh, Michael
    Neuwirth, Ales
    Kourtzelis, Ioannis
    Subramanian, Pallavi
    Mirtschink, Peter
    Peitzsch, Mirko
    Matschke, Klaus
    Tugtekin, Sems M.
    Kajikawa, Tetsuhiro
    Li, Xiaofei
    Steglich, Anne
    Gembardt, Florian
    Wegner, Annika C.
    Hugo, Christian
    Hajishengallis, George
    Chavakis, Triantafyllos
    Deussen, Andreas
    Todorov, Vladimir
    Kopaliani, Irakli
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (06)
  • [8] Role of ET-1 receptor binding and [Ca2+]i in contraction of coronary arteries from DOCA-salt hypertensive rats
    Giulumian, AD
    Molero, MM
    Reddy, VB
    Pollock, JS
    Pollock, DM
    Fuchs, LC
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (05): : H1944 - H1949
  • [9] Myocardial Remodeling in Hypertension: Toward a New View of Hypertensive Heart Disease
    Gonzalez, Arantxa
    Ravassa, Susana
    Lopez, Begona
    Moreno, Maria U.
    Beaumont, Javier
    San Jose, Gorka
    Querejeta, Ramon
    Bayes-Genis, Antoni
    Diez, Javier
    [J]. HYPERTENSION, 2018, 72 (03) : 549 - 558
  • [10] Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension
    Grabowski, Katja
    Herlan, Laura
    Witten, Anika
    Qadri, Fatimunnisa
    Eisenreich, Andreas
    Lindner, Diana
    Schaedlich, Martin
    Schulz, Angela
    Subrova, Jana
    Mhatre, Ketaki Nitin
    Primessnig, Uwe
    Plehm, Ralph
    van Linthout, Sophie
    Escher, Felicitas
    Bader, Michael
    Stoll, Monika
    Westermann, Dirk
    Heinzel, Frank R.
    Kreutz, Reinhold
    [J]. HYPERTENSION RESEARCH, 2022, 45 (02) : 292 - 307